Date: 2014-01-13
Type of information: Development agreement
Compound: Platelet Derived Growth Factor Receptor Beta (PDGFR-Beta) antibody potential combination therapy with Eylea® (aflibercept)
Company: Bayer (Germany) Regeneron Pharmaceuticals (USA - NY)
Therapeutic area: Ophtalmological diseases
Type agreement: development
Action mechanism:
Disease: wet age-related macular degeneration (wet AMD)
Details: * On January 13, 2014, Bayer HealthCare and Regeneron Pharmaceuticals have announced an agreement to jointly develop an innovative antibody to Platelet Derived Growth Factor Receptor Beta (PDGFR-β) as a potential combination therapy with Eylea® (aflibercept) for the treatment of wet age-related macular degeneration (wet AMD). Preclinical data suggests that combining PDGFR-β blockade with vascular endothelial growth factor (VEGF) blockade by EYLEA can be advantageous over inhibiting VEGF alone in the treatment of this devastating eye disease. First in human clinical studies are currently planned to begin in early 2014.
Financial terms: Under the terms of the agreement, Bayer HealthCare will make an upfront payment of $25.5 million to Regeneron and will share global development costs for the program. Bayer HealthCare will have exclusive commercialization rights to the combination product outside the US where they will share profits from ex-U.S. sales equally with Regeneron. Within the U.S., Regeneron has exclusive commercialization rights and will retain 100 percent of the profits from sales. Under the agreement, Regeneron is eligible to receive up to $40 million in option and milestone payments through regulatory approval from Bayer HealthCare, and Bayer HealthCare is responsible for certain payments due to a third party, including royalties on ex-US sales and a share of development milestones.
Latest news:
